Canada· CA-DIN-02469723
BAVENCIO
A avelumab product containing avelumab, registered in Canada by EMD SERONO, A DIVISION OF EMD INC., CANADA. The same ATC class is registered in 12 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Avelumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF04 (avelumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Avelumab · ATC L01FF04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- AVELUMAB
- Manufacturer
- EMD SERONO, A DIVISION OF EMD INC., CANADA
- Country
- Canada (CA)
- ATC code
- L01FF04
- ATC class
- Avelumab
- Defined daily dose
- 57.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for avelumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Avelumab · interactions on record
3 records
- 3 severe
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Avelumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBavencioOrifarm Oy
- SpainBAVENCIO 20 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Europe B.V.
- United StatesBAVENCIOEMD Serono, Inc.
- NorwayBavencioMerck Europe B.V.
- SwitzerlandBavencio
- IcelandBavencioMerck Europe B.V.*
- Japanアベルマブ（遺伝子組換え）メルクバイオファーマ
- NetherlandsBavencio 20 mg/ml concentraat voor oplossing voor infusieMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bavencio
- Liechtenstein · Bavencio
- Norway · Bavencio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c064585b-bd4b-413e-86af-a41ed690870a GET /v1/drugs/c064585b-bd4b-413e-86af-a41ed690870a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02469723",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01FF04",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "95856",
"strengths": [
"20 MG"
],
"ahfs_class": null,
"substances": [
"AVELUMAB"
],
"product_categorization": null
}See everything about avelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.